Compton Developments Ltd.

United Kingdom

Back to Profile

1-7 of 7 for Compton Developments Ltd. Sort by
Query
Aggregations
IP Type
        Patent 5
        Trademark 2
Jurisdiction
        United States 4
        World 3
Date
2023 2
2021 1
Before 2021 4
IPC Class
A61K 36/324 - Boswellia, e.g. frankincense 4
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids 2
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system 2
A23K 1/16 - supplemented with accessory food factors; Salt blocks 1
A23K 1/18 - specially adapted for particular animals 1
See more
NICE Class
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations 2
05 - Pharmaceutical, veterinary and sanitary products 2

1.

MAYDI+

      
Application Number 1747755
Status Registered
Filing Date 2023-07-27
Registration Date 2023-07-27
Owner Compton Developments Limited (United Kingdom)
NICE Classes  ?
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Skincare preparations; non-medicated skincare products; non-medicated skin care and cleansing preparations; soap; skin creams, skin lotions and balms; skin oils; skin gels; skin mousse and foams; aromatherapy lotions, creams & oils; essential oils; blended essential oils; massage oils. Pharmaceutical preparations and substances; nutraceuticals for therapeutic purposes; nutritional supplements and vitamins; medicated skincare preparations; medicated skin care and cleansing preparations for human use.

2.

MAYDI+

      
Serial Number 79377533
Status Registered
Filing Date 2023-07-27
Registration Date 2025-01-28
Owner Compton Developments Limited (United Kingdom)
NICE Classes  ?
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Cosmetic skincare preparations; Non-medicated skin care preparations; non-medicated toiletry preparations; moisturizing preparations for the skin, face and body, namely, lotion, cream, gel, serum, balm, oil, cleanser, soap, peel, toner; beauty masks for the face and body; hand and nail cream; non medicated heel and foot cream; cleansing preparations for the skin, face and body, namely, lotion, cream, foam, mousse, gel, serum, balm, oil, exfoliating scrub, micellar water and toner; skin cleanser; facial cleanser; non-medicated facial toner; face wash; face wipes, namely, pre-moistened cosmetic wipes; impregnated cleaning pads impregnated with cosmetics; make-up remover; body wash; skin soap; beauty soap; bath and shower soap, gel, cream, foam; bath soak, namely, non-medicated bath salts, bath oils, bath melts and bubble bath; bath bombs; anti-ageing treatments for the face, skin and body, namely, lotion, cream, gel, serum, balm, oil, cleanser, soap, peel and toner; anti-wrinkle treatments for the face, skin and body, namely, moisturizer, lotion, cream, gel, serum, balm, oil, cleanser, soap, peel and toner; wrinkle minimizing cosmetic preparations for topical facial use; cosmetic tanning preparations; non-medicated skin care preparations containing sunscreen; non-medicated hair preparations and treatments for cosmetic purposes; non-medicated hair cream, oil, mousse, serum, masks, spray, shampoo, conditioner and dry shampoo; pre-shaving and after-shaving lotions, creams and gels; make-up; make-up preparations for the face and body, namely primer, foundation, concealer; essential oils for aromatherapy use; essential oils; blended essential oils; massage oils. Pharmaceutical preparations and substances for dermatological health; Nutraceuticals for use as a dietary supplement; Nutraceuticals for the treatment of bone and joint health; Nutraceuticals for use as a dietary supplement for promoting longer, stronger, healthier hair and supporting glowing skin and strong nails; Nutraceuticals for use as a dietary supplement for alleviating peri-menopause and menopause symptoms; Nutraceutical supplement to treat inflammation; Nutraceutical supplement to improve gut health; nutritional supplements and vitamins; medicated skincare preparations; medicated skin care and cleansing preparations for human use.

3.

Inhibitor of inflammatory conditions

      
Application Number 17192133
Grant Number 12005094
Status In Force
Filing Date 2021-03-04
First Publication Date 2021-07-15
Grant Date 2024-06-11
Owner Compton Developments Ltd. (United Kingdom)
Inventor
  • Blain, Emma Jane
  • Duance, Victor Collin
  • Ali, Ahmed Yasine
  • Bowen, Ifor Delme

Abstract

Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: psoriasis, demyelinating neurological disorders including multiple sclerosis, all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, Alzheimer's Disease, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders.

IPC Classes  ?

  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
  • A61K 36/324 - Boswellia, e.g. frankincense
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

4.

Inhibitor of inflammatory conditions

      
Application Number 15227054
Grant Number 10940175
Status In Force
Filing Date 2016-08-03
First Publication Date 2017-02-23
Grant Date 2021-03-09
Owner COMPTON DEVELOPMENTS LTD. (United Kingdom)
Inventor
  • Blain, Emma Jane
  • Duance, Victor Collin
  • Ali, Ahmed Yasine
  • Bowen, Ifor Delme

Abstract

Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: inflammatory bowel disease (IBD), all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, Alzheimer's Disease, demyelinating neurological disorders including multiple sclerosis, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders.

IPC Classes  ?

  • A61K 36/324 - Boswellia, e.g. frankincense
  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids

5.

Inhibitor of inflammatory conditions

      
Application Number 13384645
Grant Number 09439936
Status In Force
Filing Date 2010-07-05
First Publication Date 2012-07-12
Grant Date 2016-09-13
Owner COMPTON DEVELOPMENTS LTD. (United Kingdom)
Inventor
  • Blain, Emma Jane
  • Duance, Victor Collin
  • Ali, Ahmed Yasine
  • Bowen, Ifor Delme

Abstract

Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: articular cartilage degradation or arthritides, osteoarthritis, rheumatoid arthritis, inflammatory bowel disease (IBD), all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, Alzheimer's Disease, demyelinating neurological disorders including multiple sclerosis, Acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders.

IPC Classes  ?

6.

INHIBITOR OF INFLAMMATORY CONDITIONS

      
Application Number GB2010001286
Publication Number 2011/010080
Status In Force
Filing Date 2010-07-05
Publication Date 2011-01-27
Owner
  • UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (United Kingdom)
  • COMPTON DEVELOPMENTS LTD (United Kingdom)
Inventor
  • Blain, Emma Jane
  • Duance, Victor Coilin
  • Ali, Ahmed Yasine
  • Bowen, Ifor, Delme

Abstract

The invention relates to Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: articular cartilage degradation or arthritides, osteoarthritis, rheumatoid arthritis, inflammatory bowel disease (IBD), all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, Alzheimer's Disease, demyelinating neurological disorders including multiple sclerosis, Acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders.

IPC Classes  ?

  • A61K 36/324 - Boswellia, e.g. frankincense
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
  • A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • A61P 5/00 - Drugs for disorders of the endocrine system
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 27/00 - Drugs for disorders of the senses
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

7.

BIOLOGICAL MATERIALS AND USES THEREOF

      
Application Number GB2009001547
Publication Number 2009/153572
Status In Force
Filing Date 2009-06-19
Publication Date 2009-12-23
Owner
  • ABERYSTWYTH UNIVERSITY (United Kingdom)
  • Compton Developments Limited (United Kingdom)
Inventor
  • Ali, Ahmed
  • Newbold, James
  • Hart, Kenton

Abstract

There is provided the use of a sandalwood extract or a sandalwood analogue as an additive to animal foodstuff for the reduction of methane production, reduction of bacterial mediated protein breakdown and reduces bacterial growth in the stomach. There are also provided food products and methods of making food products incorporating sandalwood extracts or sandalwood analogues.

IPC Classes  ?

  • A23K 1/16 - supplemented with accessory food factors; Salt blocks
  • A23K 1/18 - specially adapted for particular animals
  • A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
  • A61K 36/185 - Magnoliopsida (dicotyledons)